EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic diversity of baloxavir marboxil across rare avian species

Yo Shimazu iD, Ryo Daniel Obara, Mariko Miki, Hiromi Osaki, Yuto Yoshimoto, Marina Hayashi, Kosuke Toyoda, Miki Ozaki, Ikumi Hanada, Rei Matsumoto, Kaori Ota, Ayumi Yamaguchi und 18 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0361119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Yo Shimazu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Triazines, Pyridones, Birds, Oxazines. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JAC Environmental & Animal Protection Foundation, Environmental Restoration and Conservation Agency, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High pathogenicity avian influenza virus (HPAIV) poses a serious threat to captive rare birds. Because effective countermeasures are limited, the use of human antiviral drugs to treat HPAIV infections in captive rare birds has been considered. Although the human antiviral drug, baloxavir marboxil (BXM), is not approved for the treatment of influenza virus infection in birds, previous studies demonstrated the antiviral efficacy of BXM in experimental avian models. Pharmacokinetic studies have also revealed substantial interspecies differences following BXM administration, suggesting the need to establish species-specific dosing regimens. In this study, BXM was administered to 14 avian species to optimize dosing regimens for each species. Oral administration of BXM using different methods revealed that drug–food interactions had a limited impact on systemic drug exposure. Pharmacokinetic analysis of BXM and its active metabolite, baloxavir acid (BXA), demonstrated marked interspecies variability in drug exposure, contributing to the development of optimized dosing regimens for each species. Furthermore, systemic exposure to BXA was strongly associated with drug absorption indicators, suggesting that species-specific differences in absorption efficiency largely determine BXA exposure among avian species. This study provides a pharmacokinetic basis for the rational use of BXM in diverse avian species. It contributes to the development of practical antiviral strategies to protect captive rare birds against HPAIVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazinesPyridonesBirdsOxazinesAntiviral AgentsPyridinesThiepinsInfluenza in BirdsAnimalsMorpholinesDibenzothiepinsSpecies SpecificityAdministration, Oral

Substanzen

MorpholinesbaloxavirTriazinesDibenzothiepinsPyridonesOxazinesAntiviral AgentsPyridinesThiepins

Autor:innen und Institutionen

  • Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Laboratory for Drug Discovery and Development, Shionogi and Co., Ltd., Toyonaka, Osaka, Japan.
  • Tokyo Sea Life Park, Edogawa-ku, Tokyo, Japan.
  • Adventure World, Nishimuro-gun, Wakayama, Japan.
  • Hyogo Park of the Oriental White Stork, Toyooka, Hyogo, Japan.
  • Tama Zoological Park, Hino, Tokyo, Japan.

ORCID-Profile: Yo Shimazu, Takao Shishido, Yoshihiro Sakoda

Förderung

  • JAC Environmental & Animal Protection Foundation
  • Environmental Restoration and Conservation Agency
  • Japan Agency for Medical Research and Development
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Science and Technology Agency
  • Shionogi
  • AWS Co., Ltd.
  • Shikoku Aquarium Development Co., Ltd.

Zitieren

APA

Shimazu, Y., Obara, R. D., Miki, M., Osaki, H., Yoshimoto, Y., Hayashi, M., Toyoda, K., Ozaki, M., Hanada, I., Matsumoto, R., Ota, K., Yamaguchi, A., Toda, K., Ishii, J., Kizaki, T., Hirano, Y., Sugimoto, Y., Watanabe, Y., Saito, K., …, & Sakoda, Y. (2026). Pharmacokinetic diversity of baloxavir marboxil across rare avian species. PLOS One. https://doi.org/10.1371/journal.pone.0361119

Vancouver

Shimazu Y, Obara RD, Miki M, Osaki H, Yoshimoto Y, Hayashi M, et al. Pharmacokinetic diversity of baloxavir marboxil across rare avian species. PLOS One. 2026. doi:10.1371/journal.pone.0361119

BibTeX
@article{Shimazu2026,
  author = {Shimazu, Yo and Obara, Ryo Daniel and Miki, Mariko and Osaki, Hiromi and Yoshimoto, Yuto and Hayashi, Marina and Toyoda, Kosuke and Ozaki, Miki and Hanada, Ikumi and Matsumoto, Rei and Ota, Kaori and Yamaguchi, Ayumi and Toda, Kosuke and Ishii, Junko and Kizaki, Tsuneo and Hirano, Yuzo and Sugimoto, Yuma and Watanabe, Yukiko and Saito, Keisuke and Kaku, Masato and Ide, Izumi and Sado, Akihiro and Sakai, Hidefumi and Nishimura, Kyohei and Endo, Mayumi and Hiono, Takahiro and Isoda, Norikazu and Shishido, Takao and Ikenaka, Yoshinori and Sakoda, Yoshihiro},
  title = {Pharmacokinetic diversity of baloxavir marboxil across rare avian species},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0361119}
}
Kostenlos starten →